The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer.
 
Alvaro Moreno-Aspitia
No Relationships to Disclose
 
Eileen McCormick Holmes
No Relationships to Disclose
 
Christian Jackisch
Honoraria - GlaxoSmithKline; Roche
Travel, Accommodations, Expenses - Roche (I)
 
Evandro De Azambuja
Honoraria - Roche/Genentech
Consulting or Advisory Role - Roche/Genentech
Research Funding - Roche/Genentech (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; Roche/Genentech
 
Frances M. Boyle
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Novartis
Other Relationship - Paxman
 
David W. Hillman
No Relationships to Disclose
 
Larissa A. Korde
Honoraria - Genomic Health
Consulting or Advisory Role - Amgen
 
Debora Fumagalli
Research Funding - Novartis
 
Miguel A. Izquierdo
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Ann E. McCullough
No Relationships to Disclose
 
Antonio C. Wolff
Consulting or Advisory Role - Pfizer
Research Funding - Myriad Genetics (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Antonio Wolff has been named as inventor on one or more issued patents or pending patent applications relating to methylation in breast cancer, and has assigned his rights to JHU, and participates in a royalty sharing agreement with JHU.
 
Kathleen I. Pritchard
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Eisai; GlaxoSmithKline; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca; Eisai; GlaxoSmithKline; Novartis; Pfizer; Roche
 
Michael Untch
No Relationships to Disclose
 
Istvan Lang
No Relationships to Disclose
 
Binghe Xu
No Relationships to Disclose
 
Ian E. Smith
No Relationships to Disclose
 
Carlos H. Barrios
Honoraria - Boehringer Ingelheim; Eisai; GlaxoSmithKline; Novartis; Pfizer; Roche/Genentech; Sanofi
Consulting or Advisory Role - Boehringer Ingelheim; Eisai; GlaxoSmithKline; Novartis; Pfizer; Roche/Genentech
Research Funding - AB Science; Abbvie; Abraxis BioScience; Amgen; Asana Biosciences; Astellas Pharma; AstraZeneca; Biomarin; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Daiichi Sankyo; Exelixis; GlaxoSmithKline; GlaxoSmithKline; ImClone Systems; LEO Pharma; Lilly; Medivation; Merck; Merrimack; Millennium; Mylan; Novartis; Pfizer; Roche/Genentech; Sanofi; Taiho Pharmaceutical
 
Richard D. Gelber
Research Funding - AstraZeneca (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Jose Baselga
Leadership - Infinity Pharmaceuticals; Varian Medical Systems
Stock and Other Ownership Interests - GRAIL; Infinity Pharmaceuticals; Juno Therapeutics; PMV Pharma; Varian Medical Systems
Consulting or Advisory Role - Eli Lilly, Novartis; GRAIL
 
Martine J. Piccart-Gebhart
Consulting or Advisory Role - AstraZeneca; Crescendo Biologics; Debiopharm Group; HUYA Bioscience International; Lilly; MSD; Novartis; Periphagen; Pfizer; PharmaMar; Radius Health; Roche/Genentech
Research Funding - AstraZeneca (Inst); Crescendo Bioscience (Inst); Debiopharm Group (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Periphagen (Inst); Pfizer (Inst); PharmaMar (Inst); Radius Health (Inst); Roche/Genentech (Inst)